Pacific Edge shares fall 63% after Novitas decision

Pacific Edge shares fall 63% after Novitas decision
(Image: Pacific Edge)
Rebecca Howard
Cancer diagnostics company Pacific Edge has come out swinging against a decision by Novitas, the Medicare administrative contractor with jurisdiction for its US laboratory, that would end reimbursement for Cxbladder Triage, Detect and Monitor. The shares fell 63% to $0.050 in early trading Monday after a trading halt was lifted.According to Pacific Edge, Novitas continues to misunderstand the current standard of care in evaluating hematuria patients, fails to consider new peer-reviewed evidence and repeats its flawed analysis of the existi...

More Markets

NZ sharemarket braces for Trump's 'Liberation Day'
Markets Market Close

NZ sharemarket braces for Trump's 'Liberation Day'

The S&P/NZX 50 Index closed at 12,320.19, up 7.59 points or 0.062%.

Graham Skellern 02 Apr 2025
Westpac Bank’s Eckhold says April cut likely wrong move
Economy

Westpac Bank’s Eckhold says April cut likely wrong move

Economists are widely expecting a 25 bps rate cut next week. 

Rebecca Howard 02 Apr 2025
The simple strategy behind Dairyworks
Primary Sector

The simple strategy behind Dairyworks

Is New Zealand still fixated on the 1kg block of cheese?

Riley Kennedy 02 Apr 2025
Trump-era FX 'compounding' margin losses, analysts say
Retail

Trump-era FX 'compounding' margin losses, analysts say

"Liberation day" could make matters worse, says Kiwibank’s Kerr.

Gregor Thompson 02 Apr 2025